STOK — Stoke Therapeutics, Inc. stock price, charts and financials

Latest market price

29.56

+0.70+2.43%

Overview Short InterestFilings

STOKQT68Stoke Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

29.56+2.43%

Earnings

Up 2.4% — Reported earnings — EPS beat by 2%, revenue missed by 4%.

High confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.83	Insider Own	21.78%	Shs Outstand	62.28M	Perf Week	-1.50%

Market Cap	1.80B	Forward P/E	-	EPS next Y	-3.16	Insider Trans	-0.74%	Shs Float	46.77M	Perf Month	-11.77%

Enterprise Value	1.65B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	33.55%	Perf Quarter	-11.80%

Income	-167.70M	P/S	56.03	EPS this Y	-17.52%	Inst Trans	-	Short Ratio	22.32	Perf Half Y	-7.11%

Sales	32.08M	P/B	4.61	EPS next Y	4.86%	ROA	-38.30%	Short Interest	15.69M	Perf YTD	-9.07%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-48.84%	52W High	41.19 -28.24%	Perf Year	124.24%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-45.41%	52W Low	12.71 132.55%	Perf 3Y	381.00%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	148.43% -	Gross Margin	90.36%	Volatility	4.63% 5.11%	Perf 5Y	-5.87%

Dividend TTM	-	EV/Sales	51.28	EPS Y/Y TTM	-70.30%	Oper. Margin	-577.46%	ATR (14)	1.50	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	8.99	Sales Y/Y TTM	-	Profit Margin	-529.20%	RSI (14)	42.34	Recom	2.20

Dividend Gr. 3/5Y	-	Current Ratio	8.99	EPS Q/Q	-141.58%	SMA20	-3.87%	Beta	1.17	Target Price	48.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-96.23%	SMA50	-4.77%	Rel Volume	0.97	Prev Close	28.86

Employees	170	LT Debt/Eq	0.01	Earnings	Aug 03	SMA200	-8.83%	Avg Volume	723.38K	Price	29.56

IPO Date	Jun 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.17% -3.92%	Net Debt/EBITDA	0.93	Volume	702,913	Change	2.43%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-13-26	Initiated	Goldman Sachs	Buy	$44
Feb-23-26	Initiated	Wolfe Research	Outperform	$40
Feb-05-26	Initiated	Guggenheim	Buy	$60
Jan-12-26	Reiterated	Wedbush	Outperform	$36
Jan-05-26	Reiterated	Loop Capital Markets		$35
Jan-05-26	Reiterated	Canaccord Genuity	Buy	$28 → $36
Dec-15-25	Reiterated	UBS	Neutral	$35 → $50
Dec-15-25	Reiterated	HC Wainwright & Co.	Buy	$35 → $50
Nov-05-25	Reiterated	Canaccord Genuity	Buy	$20 → $28
Oct-10-25	Reiterated	Needham	Buy	$22 → $35

Latest News

Today

Today06:11PM

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimateszacks.com

06:04PM

Stoke Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

04:01PM

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updatesbusinesswire.com

Jul-27-26

Jul-27-2604:01PM

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updatesbusinesswire.com

Jul-19-26

Jul-19-2602:15AM

Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last StretchSeekingAlpha

Jul-16-26

Jul-16-2604:01PM

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com

Jul-13-26

Jul-13-2605:43AM

Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44Benzinga

Jun-30-26

Jun-30-2608:00AM

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndromebusinesswire.com

Company

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	184	37	9	12	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	2	0	0	0
Gross Profit	184	37	9	12	0	-2	0	0	0
Selling, General and Administrative Excl. Other	67	49	41	39	32	21	12	4	2
Research and Development	138	89	82	78	54	32	23	8	4
Other Operating Expense	0	0	1	0	0	-2	0	1	0
Operating Income	-21	-101	-115	-104	-86	-53	-36	-13	-6
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	14	12	10	3	0	1	3	0	0
Net Income Before Taxes	-7	-89	-105	-101	-86	-52	-32	-13	-6
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-7	-89	-105	-101	-86	-52	-32	-13	-6
Net Income From Continuing Operations	-7	-89	-105	-101	-86	-52	-32	-13	-6
Net Income	-7	-89	-105	-101	-86	-52	-32	-13	-6
EPS (Recurring)	-0.12	-1.65	-2.38	-2.60	-2.34	-1.56	-1.59	-0.53	-0.24
EPS (Basic, Before Extraordinaries)	-0.12	-1.65	-2.38	-2.60	-2.34	-1.56	-1.59	-0.53	-0.24
EPS (Diluted)	-0.12	-1.65	-2.38	-2.60	-2.34	-1.56	-1.59	-0.53	-0.24
EBITDA	-5	-87	-102	-100	-85	-50	-32	-13	-5
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	10.18	16.10	25.72	30.00	—	—	—	—	—
Gross Margin	100.00	100.00	100.00	100.00	—	—	—	—	—
Operating Margin	-11.41	-272.97	-1,277.78	-866.67	—	—	—	—	—
Net Margin	-3.80	-240.54	-1,166.67	-841.67	—	—	—	—	—
Shares Outstanding	59	54	44	39	37	33	18	24	24
Market Capitalization	1,873	596	231	360	888	2,044	510	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '26	Sale	32.66	7,228	236,068	27,598	Jul 06
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Jun 16 '26	Sale	29.95	1,457	43,637	18,086	Jun 18
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 01 '26	Sale	30.58	1,795	54,891	34,826	Jun 03
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '26	Sale	32.79	2,243	73,548	36,621	May 05
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '26	Sale	32.66	1,838	60,029	38,864	Apr 03
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 20 '26	Sale	33.69	9,293	313,038	19,543	Mar 24
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Sale	29.99	1,461	43,815	40,702	Mar 19
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Option Exercise	2.19	1,365	2,989	42,163	Mar 19
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '26	Sale	31.34	4,628	145,062	28,836	Mar 19
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '26	Sale	31.34	6,686	209,569	40,798	Mar 19
Leggett Thomas	Chief Financial Officer	Mar 18 '26	Sale	31.34	2,382	74,663	10,172	Mar 19
Hoitt Jason	Chief Patient Officer	Mar 18 '26	Sale	31.34	1,931	60,527	10,276	Mar 19
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	33.01	6,164	203,451	47,484	Mar 19
Hoitt Jason	Chief Patient Officer	Mar 17 '26	Sale	33.01	1,781	58,785	12,207	Mar 19
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 17 '26	Sale	33.01	4,267	140,838	33,464	Mar 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.